Table 1.
Patients’ Characteristics and Treatment
| Overall | G-B | G-CHOP | P | |
|---|---|---|---|---|
| Total number | 114 | 61 | 49 | – |
| Age (y) (median/range) | 63/33–86 | 66/36–83 | 59/33–75 | 0.001a |
| Sex | ||||
| Male | 43 (37.7%) | 23/61 (37.7%) | 19/49 (38.8%) | |
| Female | 71 (62.3%) | 38/61 (62.3%) | 30/49 (61.2%) | 0.909 |
| FL type | <0.001a | |||
| 1 | 45 (39.5%) | 33 (54.1%) | 9 (18.4%) | |
| 2 | 28 (24.6%) | 15 (24.6%) | 12 (24.5%) | |
| 3A | 27 (23.7%) | 3 (4.9%) | 24 (49%) | |
| Indolent unspecified | 14 (12.3%) | 10 (16.4%) | 4 (8.2%) | |
| FLIPI | 2.5 IQR (2–3) | 3 IQR (2–3) | 2 IQR (2–3) | 0.159 |
| IPI | 2 IQR (1–3) | 2 IQR (2–3) | 2 IQR (1–2) | 0.116 |
| IgG levels prior therapy (g/L) | 10.1 ± 2.9 | 10.6 ± 3.2 | 9.8 ± 2.5 | 0.155 |
| Hosp. for first G application | 49 (43.0%) | 21 (34.4%) | 26 (53.1%) | 0.050a |
| No. cycles | 6 IQR (6–6) | 6 IQR (6–6) | 6 IQR (6–8) | 0.350 |
| Total G dose | 8 IQR (8–10) | 8 IQR (8–10) | 9 IQR (8–10) | 0.277 |
| Interruption due to AE | 41 (36.0%) | 19 (31.1%) | 19 (38.8%) | 0.403 |
| G-CSF prophylaxis | 0.135 | |||
| None | 35 (30.7%) | 23 (37.7%) | 10 (20.4%) | |
| Primary | 66 (57.9%) | 31 (50.8%) | 33 (67.3%) | |
| Secondary | 13 (11.4%) | 7 (11.5%) | 6 (12.2%) | |
| Pts starting maintenance/ Pts. responding to induction | 90 (84.1%) | 43 (78.2%) | 44 (89.8%) | 0.122 |
| No. cycles of maintenance | 3 IQR (1–6) | 2 IQR (0–5) | 5 IQR (2–8) | <0.001a |
| Pts. interrupting maintenance/pts. starting maintenance | 34 (37.8%) | 16 (37.2%) | 17 (38.6%) | 0.891 |
aStatistically significant at level P < 0.05.
CHOP = CVP + doxorubicine; CVP = cyclophosphamide, vincristine and glucocorticoid; FL = follicular lymphoma; IQR = interquartile range.